Excessive pre-HIFU PSA ranges in intermediate-risk prostate most cancers have been linked to elevated recurrence and remedy failure, per ASCO 2025 analysis.Amongst sufferers...
The remedy mixture of Calquence (acalabrutinib) plus bendamustine and Rituxan (rituximab) was just lately granted full approval by the Meals and Drug Administration (FDA)...
Breyanzi confirmed important efficacy and sturdy responses in adults with relapsed or refractory marginal zone lymphoma within the section 2 TRANSCEND FL trial.Amongst...
Talzenna plus Xtandi improved total survival in HRR-deficient mCRPC by 14 months and lowered demise danger by 38%, per TALAPRO-2 trial information.Amongst sufferers...
